1 Oscarson M, "homepage of the cytochrome P450 allele nomenclature committee" 2003
2 Sonnichsen DS, "Variability in human cytochrome P450 paclitaxel metabolism" 275 : 566-575, 1995
3 Gaedigk A, "Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans" 72 : 76-89, 2002
4 Iyer L, "UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity" 2 : 43-47, 2002
5 Sullivan-Klose TH, "The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism" 6 : 341-349, 1996
6 Ojeda SR, "The role of arachidonic acid and its metabolites in the release of neuropeptides" 559 : 192-207, 1989
7 de Morais SM, "The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans" 269 : 15419-22, 1994b
8 Taylor HL, "The isolation and structure of taxol a novel antileukemic and antitumor agent from Taxus brevifolia" 2325-27,
9 Cresteil T, "Taxol metabolism by human liver microsomes:identification of cytochrome P450 isozymes involved in its biotransformation" 54 : 386-92, 1994
10 Walle T, "Taxol metabolism and disposition in cancer patients" 23 : 506-512, 1995
1 Oscarson M, "homepage of the cytochrome P450 allele nomenclature committee" 2003
2 Sonnichsen DS, "Variability in human cytochrome P450 paclitaxel metabolism" 275 : 566-575, 1995
3 Gaedigk A, "Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans" 72 : 76-89, 2002
4 Iyer L, "UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity" 2 : 43-47, 2002
5 Sullivan-Klose TH, "The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism" 6 : 341-349, 1996
6 Ojeda SR, "The role of arachidonic acid and its metabolites in the release of neuropeptides" 559 : 192-207, 1989
7 de Morais SM, "The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans" 269 : 15419-22, 1994b
8 Taylor HL, "The isolation and structure of taxol a novel antileukemic and antitumor agent from Taxus brevifolia" 2325-27,
9 Cresteil T, "Taxol metabolism by human liver microsomes:identification of cytochrome P450 isozymes involved in its biotransformation" 54 : 386-92, 1994
10 Walle T, "Taxol metabolism and disposition in cancer patients" 23 : 506-512, 1995
11 Rae JM, "Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays" 299 (299): 849-857, 2001
12 Dai D, "Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid" 11 : 597-607, 2001
13 Gaedigk A, "Optimization of cytochrome P4502D6 phenotype assignment using a genotyping algorithm based on allele frequency data" 9 (9): 669-682, 1998
14 Shimada T, "Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs studies with liver microsomes of 30 Japanese and 30 Caucasians" 4140-3, jpharmacolexpther1994
15 Johansson I, "Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine" 90 : 11825-9, 1993
16 Cho J, "Identification of polymorphisms in human CYP2C8 gene by two dimensional gel scanning in healthy Koreans" 2 : 2003
17 Lasker JM, "Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney" 275 : 4118-4126, 2000
18 Soyama A, "Five novel single nucleotide polymorphisms in the CYP2C8 gene one of which induces a frame-shift" 17 : 374-377, 2002
19 Mathijssen RH, "Effects of St John's wort on irinotecan metabolism" 94 : 1247-1249, 2002
20 McGiff JC, "Cytochrome P-450 metabolism of arachidonic acid Annu Rev Pharmacol Toxicol 1991" 339-69,
21 McGiff JC, "Cytochrome P-450 metabolism of arachidonic acid" 31 : 339-69, 1991
22 McGuire WP, "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer" 334 : 1-6, 1996
23 Balkwell F, "Current research and treatment for epithelial ovarian cancer" 39 : 1818-1827, 2003
24 Kumar G, "Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol" 36 : 129-135, 1995
25 Luo G, "Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid" 357 : 45-57, 1998
26 Goldstein JA, "Clinical relevance of genetic polymorphisms in the human CYP2C subfamily" 2001
27 Mathijssen RH, "Clinical pharmacokinetics and metabolism of irinotecan" 7 : 2182-2194, 2001
28 Advanced Ovarian cancer Trialists Group, "Chemotherapy in advanced ovarian cancer:overview of randomized clinical trials" 303 : 884-91, 1991
29 Bahadur N, "CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes" 64 : 1579-1589, 2002
30 Nomura E, "CYP1A1 polymorphism and risk of gynecologic malignancy in Japan" 13 (13): 785-790, 2003
31 Goldstein JA, "Biochemistry and molecular biology of the human CYP2C subfamily" 4 : 285-99, 1994
32 Node K, "Antiinflammatory properties of cytochrome P450 epoxygenasederived eicosanoids" 285 : 1276-1279, 1999
33 Tateishi T, "Analysis of the CYP2D6 gene in relation to dextromethorphan O- demethylation capacity in a Japanese population" 65 : 570-575, 1999
34 Soyama A, "Amiodarone N-deethylation by CYP2C8 and its variants" 91 : 174-178, 2002
35 Memarzadeh S, "Advances in the management of epithelial ovarian cancer" 46 : 621-630, 2001
36 Berek JS, "Advanced epithelial ovarian cancer" 10 : 87-92, 1999
국립중앙도서관 "우편 복사 서비스"로 연결 됩니다.
KCI
KISS
